ARTICLE | Clinical News
Motesanib diphosphate: Phase III data
February 23, 2015 8:00 AM UTC
The double-blind, Asian Phase III MONET-A trial in 401 patients with advanced non-squamous NSCLC showed that motesanib plus paclitaxel and carboplatin missed the primary endpoint of improving PFS vs. ...